Characteristics of patients and controls
. | PV-WHO . | PV-PVSG . | SE . | Controls . |
|---|---|---|---|---|
| n | 64 | 7 | 11 | 80 |
| Age, y, mean (range) | 60 (19-83) | 67 (35-82) | 58 (41-80) | 34 (18-73) |
| Duration of disease, y, mean (range) | 7.4 (0.1-33) | 10.8 (2-26) | 7 (0.1-50) | 0 |
| Males | 38 | 2 | 10 | 43 |
| Females | 30 | 5 | 1 | 37 |
| Any cytoreductive pretreatment | 32 | 4 | 0 | 0 |
| Pretreatment by IFN-α | 5 | 0 | 0 | 0 |
. | PV-WHO . | PV-PVSG . | SE . | Controls . |
|---|---|---|---|---|
| n | 64 | 7 | 11 | 80 |
| Age, y, mean (range) | 60 (19-83) | 67 (35-82) | 58 (41-80) | 34 (18-73) |
| Duration of disease, y, mean (range) | 7.4 (0.1-33) | 10.8 (2-26) | 7 (0.1-50) | 0 |
| Males | 38 | 2 | 10 | 43 |
| Females | 30 | 5 | 1 | 37 |
| Any cytoreductive pretreatment | 32 | 4 | 0 | 0 |
| Pretreatment by IFN-α | 5 | 0 | 0 | 0 |
Diagnosis of patients as indicated by the participating center.